,NCT_ID,Title,Drugs
0,NCT03178851,A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti-PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma,"['Atezolizumab', 'Cobimetinib', 'Atezolizumab', 'Atezolizumab']"
1,NCT03340558,A Pilot Study Investigating the Effect of Atezolizumab Monotherapy and Atezolizumab Plus Cobimetinib on the Tumoral Immunoprofile in Liver Metastases From Colorectal Cancer,"['Atezolizumab', 'Cobimetinib']"
2,NCT03946358,A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive Cancers,"['Blood sample collection', 'Atezolizumab', 'UCPVax']"
3,NCT03802604,Combination of Talimogene Laherparepvec With Atezolizumab in Patients With Residual Breast Cancer After Standard Neoadjuvant Multi-agent Chemotherapy (PROMETEO TRIAL),"['Talimogene laherparepvec', 'Atezolizumab']"
4,NCT03073525,"A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers","['Vigil', 'Atezolizumab']"
5,NCT05694013,Interventional Platform Study Investigating the Impact of Digital Health Solutions on Health Outcomes and Health-Care Resource Utilization in Participants Receiving Systemic Treatment in Clinical Practice,['Atezolizumab SC']
6,NCT03281369,"A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","['5-Fluorouracil (5-FU)', 'Leucovorin', 'Oxaliplatin', 'Atezolizumab', 'Cobimetinib', 'Ramucirumab', 'Paclitaxel', 'PEGylated recombinant human hyaluronidase (PEGPH20)', 'BL-8040', 'Linagliptin', 'Atezolizumab', 'Cobimetinib', 'Cisplatin', 'Tiragolumab', '5-Fluorouracil (5-FU)']"
7,NCT02715531,"An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors","['5-FU', 'Atezolizumab', 'Bevacizumab', 'Gemcitabine', 'Leucovorin', 'Nab-Paclitaxel', 'Oxaliplatin', 'Capecitabine', 'Cisplatin']"
8,NCT03622593,"A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)","['Aflibercept', 'Faricimab']"
9,NCT03622580,"A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE)","['Aflibercept', 'Faricimab']"
10,NCT04341181,ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling,"['Alectinib', 'Atezolizumab', 'Avelumab', 'Axitinib', 'Erlotinib', 'Vemurafenib plus Cobimetinib (combination)', 'Trastuzumab plus Pertuzumab (combination)', 'Trastuzumab emtansine', 'Vismodegib', 'Niraparib']"
11,NCT05722886,"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations","['Alectinib', 'Atezolizumab', 'Entrectinib', 'Trastuzumab in combination with pertuzumab', 'Vemurafenib in combination with cobimetinib']"
12,NCT02013219,A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer,"['Alectinib', 'Atezolizumab', 'Erlotinib']"
13,NCT05525858,KOrean Precision Medicine Networking Group Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II,"['Alectinib', 'Atezolizumab', 'Erlotinib', 'Trastuzumab + Pertuzumab', 'Trastuzumab emtansine', 'Vemurafenib', 'Bevacizumab + Erlotinib', 'Entrectinib']"
14,NCT03178552,A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial),"['Alectinib', 'Atezolizumab', 'Pemetrexed', 'Cisplatin', 'Carboplatin', 'Gemcitabine', 'Entrectinib', 'Cobimetinib', 'Vemurafenib', 'Bevacizumab', 'GDC-6036', 'Docetaxel']"
15,NCT04302025,"NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer","['Alectinib', 'Entrectinib', 'Vemurafenib', 'Cobimetinib', 'Pralsetinib', 'Atezolizumab', 'SBRT', 'Chemotherapy']"
16,NCT03498521,"A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy","['Alectinib', 'Vismodegib', 'Ipatasertib', 'Olaparib', 'Erlotinib', 'Bevacizumab', 'Vemurafenib', 'Cobimetinib', 'Trastuzumab Subcutaneous (SC)', 'Pertuzumab', 'Atezolizumab', 'Carboplatin', 'Paclitaxel', 'Cisplatin', 'Gemcitabine', 'Entrectinib', 'Ivosidenib', 'Pemigatinib']"
17,NCT03767075,"Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours",['Arm 1 - atezolizumab']
18,NCT03686332,PERICLES (PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study)-a Phase 2 Study of Atezolizumab With or Without Radiotherapy in Penile Cancer,"['Arm A: Atezolizumab and Radiotherapy', 'Arm B: Atezolizumab']"
19,NCT03915678,Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors,"['Association atezolizumab + BDB001 + RT', 'Association atezolizumab + BDB001+ RT', 'Association atezolizumab + BDB001+ RT', 'Association atezolizumab + BDB001 + RT', 'Association atezolizumab + BDB001 + RT', 'Association atezolizumab + BDB001 + RT']"
20,NCT03148418,"An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study",['Atezolizumab']
21,NCT05112965,"An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)",['Atezolizumab']
22,NCT03768063,"An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)",['Atezolizumab']
23,NCT05171777,"A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer",['Atezolizumab']
24,NCT03782207,"A Non-Interventional, Multicenter, Multiple Cohort Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice",['Atezolizumab']
25,NCT03330886,An Observational Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina,['Atezolizumab']
26,NCT03922997,"An Open-Label, Singe Arm, Multicenter Study to Investigate the Safety and Efficacy of Atezolizumab (Tecentriq) in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",['Atezolizumab']
27,NCT03559647,The Effectiveness Of Atezolizumab Under Real-World Conditions In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy,['Atezolizumab']
28,NCT03399643,Non-Interventional Study To Investigate The Effectiveness Of Atezolizumab Under Real-World Conditions In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce),['Atezolizumab']
29,NCT03232593,Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s),['Atezolizumab']
30,NCT02951767,"A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",['Atezolizumab']
31,NCT02928406,"An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract",['Atezolizumab']
32,NCT02541604,"An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) In Pediatric and Young Adult Patients With Previously Treated Solid Tumors",['Atezolizumab']
33,NCT02450331,"A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection",['Atezolizumab']
34,NCT02108652,"A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer",['Atezolizumab']
35,NCT02031458,"A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer",['Atezolizumab']
36,NCT04321330,"An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma",['Atezolizumab']
37,NCT03285763,"A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)",['Atezolizumab']
38,NCT02848651,A Phase II Single-Arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Clinical Evaluation of Novel Blood-Based Diagnostics,['Atezolizumab']
39,NCT05470595,"A Phase II, Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung",['Atezolizumab']
40,NCT04865250,"Exploratory Study Evaluating the Potential of Immune Signature Profiling for Predicting Response in Patients With Resectable Stage II, IIIA and Select IIIB (T3N2 Only) Non-squamous Non-Small Cell Lung Cancer (NSCLC) to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel",['Atezolizumab']
41,NCT03697850,Phase II Study of Maintenance Anti-PD-L1 Treatment With Atezolizumab After Chemo-radiotherapy for Muscle-infiltrating Bladder Cancer Patients Not Eligible for Radical Cystectomy: Bladder Sparing,['Atezolizumab']
42,NCT04624399,Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer,['Atezolizumab']
43,NCT04408118,Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combination With Paclitaxel and Bevacizumab (Avastin®) in Patients With Advanced or Metastatic Triple-negative Breast Cancer,['Atezolizumab']
44,NCT04273061,Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention,['Atezolizumab']
45,NCT04221529,Single-Arm Phase II-Study in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) With Poor Performance Status Receiving Atezolizumab-Carboplatin-Etoposide,['Atezolizumab']
46,NCT03357224,Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment,['Atezolizumab']
47,NCT03262454,Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for Recurrent or Refractory Small Cell Lung Cancer,['Atezolizumab']
48,NCT05118724,Perioperative/Adjuvant Atezolizumab With or Without the Immunomodulatory IMM-101 in Patients With MSI-high or MMR-deficient Stage III Colorectal Cancer Ineligible for Oxaliplatin-based Chemotherapy - a Randomized Phase II Study,['Atezolizumab']
49,NCT05038657,"Atezolizumab in Patients With Urinary Tract Squamous Cell Carcinoma: a Single Arm, Open Label, Multicentre, Phase II Clinical Trial",['Atezolizumab']
50,NCT03976518,"Phase II, Open-label Study of Atezolizumab in a Cohort of Pretreated, Advanced Non-small Cell Lung Cancer (NSCLC) Patients With Rare Histological Subtypes (CHANCE Trial).",['Atezolizumab']
51,NCT03228368,The Predicted Potential of Quantitative T Cell Repertoire(TCR) Analysis Using Next-generation Sequencing (NGS) in Anti-PD-L1 Treatment in Non Small Cell Lung（NSCLC) Cancer Patients,['Atezolizumab (MPDL3280A)']
52,NCT02409342,"A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer","['Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody', 'Carboplatin', 'Cisplatin', 'Gemcitabine', 'Pemetrexed']"
53,NCT02302807,"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy","['Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody', 'Docetaxel', 'Paclitaxel', 'Vinflunine']"
54,NCT02631577,A Phase Ib/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,"['Atezolizumab (MPDL3280A) [TECENTRIQ]', 'Lenalidomide', 'Obinutuzumab']"
55,NCT02927301,"A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer","['Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody']"
56,NCT02366143,"A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer","['Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody', 'Bevacizumab', 'Carboplatin', 'Paclitaxel']"
57,NCT02420821,"A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma","['Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody', 'Bevacizumab', 'Sunitinib']"
58,NCT01984242,"A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma","['Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody', 'Bevacizumab', 'Sunitinib']"
59,NCT02763579,"A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","['Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody', 'Carboplatin', 'Etoposide', 'Placebo']"
60,NCT02367781,"A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer","['Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody', 'Carboplatin', 'Nab-Paclitaxel', 'Pemetrexed']"
61,NCT02431208,A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation),"['Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody', 'Daratumumab', 'Lenalidomide', 'Pomalidomide', 'Dexamethasone']"
62,NCT02813785,"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy","['Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody', 'Docetaxel']"
63,NCT03456063,"A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","['Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody', 'Placebo Comparator', 'Nab-paclitaxel', 'Pemetrexed', 'Carboplatin', 'Cisplatin', 'Gemcitabine']"
64,NCT03191786,"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy","['Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody', 'Vinorelbine', 'Gemcitabine']"
65,NCT03125902,"A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer","['Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody', 'Atezolizumab Placebo', 'Paclitaxel']"
66,NCT02788279,"A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma","['Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody', 'Cobimetinib', 'Regorafenib']"
67,NCT02425891,"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer","['Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody', 'Nab-Paclitaxel', 'Placebo']"
68,NCT03197935,A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer,"['Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody', 'Placebo', 'Nab-paclitaxel', 'Doxorubicin', 'Cyclophosphamide', 'Filgrastim', 'Pegfilgrastim']"
69,NCT02367794,"A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer","['Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody', 'Carboplatin', 'Nab-Paclitaxel', 'Paclitaxel']"
70,NCT02458638,"An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors","['Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody']"
71,NCT03280563,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)","['Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody', 'Bevacizumab', 'Entinostat', 'Exemestane', 'Fulvestrant', 'Ipatasertib', 'Tamoxifen', 'Abemaciclib']"
72,NCT02410512,"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors","['Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody', 'MOXR0916, a humanized agonist anti-OX40 monoclonal antibody']"
73,NCT02729896,A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,"['Atezolizumab [TECENTRIQ]', 'Obinutuzumab', 'Polatuzumab Vedotin', 'Rituximab']"
74,NCT02891824,"A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab","['atezolizumab + avastin + platinum-based chemotherapy', 'placebo + avastin + platinum-based chemotherapy']"
75,NCT04759248,A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study,['Atezolizumab + Trastuzumab + Vinorelbine']
76,NCT04487756,Phase Ib/II Trial of the Combination of Atezolizumab With Dendritic Cell Vaccination as Maintenance Treatment in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) After Induction Treatment,"['Atezolizumab 1200 mg in 20 ML Injection', 'ADC Vaccine', 'Carboplatin']"
77,NCT04602078,"Phase II, Multicenter, Non-randomized, Single-arm, Open-label Trial of Atezolizumab in Combination of Split-doses of Gemcitabine Plus Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","['Atezolizumab 1200 mg/m2', 'Gemcitabine 1000 mg/m2', 'Cisplatin 70 mg/m2']"
78,NCT04770272,An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono),"['Atezolizumab 840 MG in 14 ML Injection', 'Atezolizumab 1200 MG in 20 ML Injection', 'Carboplatin', 'Paclitaxel', 'Epirubicin', 'Cyclophosphamide']"
79,NCT04059887,Evaluation of Blood Tumor Mutation Burden (TMB) for Improved Efficacy of Atezolizumab in 2nd Line Non-small Cell Lung Cancer (NSCLC) [BUDDY],['Atezolizumab Injection [Tecentriq]']
80,NCT04186013,Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer (Study ATEZOBLADDERPRESERVE),['Atezolizumab Injection [Tecentriq]']
81,NCT05180006,Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy,"['Atezolizumab Injection', 'Ipatasertib', 'Bevacizumab', 'Pertuzumab', 'Trastuzumab']"
82,NCT04862949,Organ-specific Responses to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma,['Atezolizumab plus bevacizumab']
83,NCT05661188,Phase II Study of Atezolizumab Plus Tiraglolumab in Combination With Chemoradiotherapy in Localized Squamous Cell Carcinoma of the Anal Canal,['Atezolizumab plus Tiraglolumab']
84,NCT02792192,"A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With or Without Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer","['Atezolizumab', 'Bacille Calmette-Guérin']"
85,NCT05300282,A Phase I/II b (Randomized Controlled) Study of Atezolizumab Combined to BEGEV Regimen as First Salvage Treatment in Patients With Relapsed or Refractory Hodgkin's Lymphoma Candidate to Autologous Stem-Cell Transplantation,['Atezolizumab']
86,NCT02908672,"A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma","['Atezolizumab', 'Atezolizumab Placebo', 'Cobimetinib', 'Vemurafenib', 'Vemurafenib Placebo']"
87,NCT02508870,A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes,"['Atezolizumab', 'Azacitidine']"
88,NCT04712643,"A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma","['Atezolizumab', 'Becavizumab']"
89,NCT02596971,A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Lymphoma,"['Atezolizumab', 'Bendamustine', 'Cyclophosphamide', 'Doxorubicin', 'Obinutuzumab', 'Prednisone', 'Vincristine', 'Rituximab']"
90,NCT04732286,"A Phase IIIb, Single Arm, Multicenter Study of Atezolizumab in Combination With Bevacizumab to Investigate Safety and Efficacy in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy","['Atezolizumab', 'Bevacizumab']"
91,NCT04487067,"A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista","['Atezolizumab', 'Bevacizumab']"
92,NCT04426825,"A Single Arm, Phase II Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Pretreated With Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitors","['Atezolizumab', 'Bevacizumab']"
93,NCT04102098,"A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","['Atezolizumab', 'Bevacizumab']"
94,NCT04091217,Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma,"['Atezolizumab', 'Bevacizumab']"
95,NCT03693573,"An Open Label, Phase IIIB, Single Arm, Multicenter Safety Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma","['Atezolizumab', 'Bevacizumab']"
96,NCT04563338,An Exploratory Evaluation of the Evolution of the Tumor Immune Microenvironment in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases Treated With Atezolizumab and Bevacizumab (INTEGRATE),"['Atezolizumab', 'Bevacizumab']"
97,NCT04017455,Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN),"['Atezolizumab', 'Bevacizumab']"
98,NCT03272217,A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer,"['Atezolizumab', 'Bevacizumab']"
99,NCT04245085,"A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance","['Atezolizumab', 'Bevacizumab', 'Carboplatin', 'Paclitaxel', 'Pemetrexed']"
100,NCT03556839,"A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix","['Atezolizumab', 'Bevacizumab', 'Cisplatin/Carboplatin', 'Paclitaxel']"
101,NCT02876224,"A Phase Ib Open-Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Bevacizumab and Immunotherapy When Administered in Patients With Gastrointestinal and Other Tumors","['Atezolizumab', 'Bevacizumab', 'Cobimetinib']"
102,NCT02174172,"A Phase Ib Study of The Safety And Pharmacology of Atezolizumab (Anti-Pd-L1 Antibody) Administered With Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors","['Atezolizumab', 'Bevacizumab', 'Interferon alfa-2b', 'Ipilimumab', 'Obinutuzumab', 'PEG-interferon alfa-2a']"
103,NCT03698461,Comparative Analysis of Immune Profile Following Neoadjuvant Chemotherapy in Colorectal Liver Metastases (CRLM): A Prospective Pilot Clinical Trial,"['Atezolizumab', 'Bevacizumab', 'Oxaliplatin', 'Levoleucovorin', '5-FU']"
104,NCT03063762,"An Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase 1b Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 in Combination With Atezolizumab ± Bevacizumab in Patients With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma","['Atezolizumab', 'Bevacizumab', 'RO6874281']"
105,NCT03434379,"A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma","['Atezolizumab', 'Bevacizumab', 'Sorafenib']"
106,NCT04524871,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","['Atezolizumab', 'Bevacizumab', 'Tiragolumab', 'Tocilizumab', 'TPST-1120', 'RO7247669 2100 mg', 'Bevacizumab', 'RO7247669 600 mg', 'RO7247669 1200 mg dose']"
107,NCT04677504,"A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer","['Atezolizumab', 'Bevacizumab', 'Cisplatin', 'Gemcitabine']"
108,NCT04338269,"A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment","['Atezolizumab', 'Cabozantinib']"
109,NCT03448835,"Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Non-metastatic, Resectable Gastric and GE-junction Cancer: The PANDA Trial","['Atezolizumab', 'Capecitabine', 'Oxaliplatin', 'Docetaxel']"
110,NCT05251948,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma (MORPHEUS C-Gastric and Gastroesophageal Junction Carcinoma)","['Atezolizumab', 'Capecitabine', 'Oxaliplatin', 'Tiragolumab']"
111,NCT02409355,"A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Gemcitabine+Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer","['Atezolizumab', 'Carboplatin', 'Cisplatin', 'Gemcitabine']"
112,NCT02657434,"A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer","['Atezolizumab', 'Carboplatin', 'Cisplatin', 'Pemetrexed']"
113,NCT04028050,"A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - MAURIS","['Atezolizumab', 'Carboplatin', 'Etoposide']"
114,NCT02807636,"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma","['Atezolizumab', 'Carboplatin', 'Gemcitabine', 'Cisplatin']"
115,NCT02350673,"A Phase 1b, Open-Label, Multi-Center, Dose Escalation Study of the Safety, Pharmacokinetics, and Therapeutic Activity of Cergutuzumab Amunaleukin, an Immunocytokine, Which Consists of a Variant of Interleukin 2 (IL 2v), That Targets Carcinoembryonic Antigen (CEA), and Atezolizumab, an Antibody That Targets Programmed Death-Ligand 1 (PD-L1), Administered Intravenously, in Patients With Locally Advanced and/or Metastatic Solid Tumors","['Atezolizumab', 'Cergutuzumab Amunaleukin']"
116,NCT04622228,"Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer","['Atezolizumab', 'Cisplatin', 'Carboplatin', 'Etoposide']"
117,NCT02486718,"A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer","['Atezolizumab', 'Cisplatin', 'Vinorelbine', 'Docetaxel', 'Gemcitabine', 'Pemetrexed']"
118,NCT01988896,A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors,"['Atezolizumab', 'Cobimetinib']"
119,NCT03395899,"A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer","['Atezolizumab', 'Cobimetinib', 'Ipatasertib', 'Bevacizumab']"
120,NCT03337698,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)","['Atezolizumab', 'Cobimetinib', 'RO6958688', 'Docetaxel', 'CPI-444', 'Pemetrexed', 'Carboplatin', 'Gemcitabine', 'Linagliptin', 'Tocilizumab', 'Ipatasertib', 'Bevacizumab', 'Sacituzumab Govitecan', 'Evolocumab']"
121,NCT02008227,"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy","['Atezolizumab', 'Docetaxel']"
122,NCT03340376,Prospective Randomized Phase II Trial Comparing Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer,"['Atezolizumab', 'Doxorubicin']"
123,NCT02323191,"Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Phase to Evaluate the Safety, Pharmacokinetics, and Activity of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Administered in Combination in Patients With Advanced Solid Tumors","['Atezolizumab', 'Emactuzumab']"
124,NCT03369964,A Phase Ib Study of The Safety and Pharmacology of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,"['Atezolizumab', 'Emactuzumab', 'Obinutuzumab']"
125,NCT03869190,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","['Atezolizumab', 'Enfortumab Vedotin', 'Niraparib', 'Magrolimab (Hu5F9-G4)', 'Tiragolumab', 'Sacituzumab Govitecan', 'Tocilizumab', 'Cisplatin', 'Gemcitabine']"
126,NCT03016312,"A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen","['Atezolizumab', 'Enzalutamide']"
127,NCT02298153,A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110),"['atezolizumab', 'epacadostat']"
128,NCT02471846,"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0919 Administered With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors","['Atezolizumab', 'GDC-0919']"
129,NCT02825940,"A Phase I, Open-Label Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously as a Single Agent or in Combination With Chemotherapy in Chinese Patients With Locally Advanced or Metastatic Solid Tumors","['Atezolizumab', 'Gemcitabine', 'Cisplatin']"
130,NCT02892318,A Phase Ib Study Evaluating the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Immunomodulatory Agents in Patients With Acute Myeloid Leukemia,"['Atezolizumab', 'Guadecitabine']"
131,NCT03922477,"A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia","['Atezolizumab', 'Hu5F9-G4']"
132,NCT05498896,"A Randomised, Open-label Phase II Study to Determine the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in Women With Triple-negative Breast Cancer","['Atezolizumab', 'Ipatasertib', 'Paclitaxel', 'Doxorubicin', 'Cyclophosphamide']"
133,NCT04177108,"A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.","['Atezolizumab', 'Ipatasertib', 'Paclitaxel', 'Placebo for Atezolizumab', 'Placebo for Ipatasertib']"
134,NCT04770896,"A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","['Atezolizumab', 'Lenvatinib', 'Sorafenib']"
135,NCT05091567,"A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab","['Atezolizumab', 'Lurbinectedin', 'Carboplatin', 'Etoposide']"
136,NCT05689671,Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma,"['Atezolizumab', 'Nab paclitaxel', 'Carboplatin', 'Pembrolizumab', 'Cisplatin', 'Carboplatin', 'Pemetrexed']"
137,NCT04148911,"An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","['Atezolizumab', 'Nab-Paclitaxel']"
138,NCT02220842,A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,"['Atezolizumab', 'Obinutuzumab', 'Tazemetostat']"
139,NCT03276468,"A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas","['Atezolizumab', 'Obinutuzumab', 'Venetoclax']"
140,NCT03498716,"A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer","['Atezolizumab', 'Paclitaxel', 'Dose-dense Doxorubicin or dose-dense Epirubicin', 'Cyclophosphamide']"
141,NCT03164993,ALICE: A Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer,"['Atezolizumab', 'Pegylated liposomal doxorubicin', 'Cyclophosphamide']"
142,NCT03498222,"Phase I Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin (ADIAtezoPemCarbo) (iTRAP Study)","['Atezolizumab', 'Pemetrexed', 'Carboplatin', 'ADI PEG20']"
143,NCT05047250,"A Phase III, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","['Atezolizumab', 'Pemetrexed', 'Carboplatin', 'Cisplatin', 'Gemcitabine', 'Paclitaxel']"
144,NCT03452137,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck","['Atezolizumab', 'Placebo']"
145,NCT04194203,"A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","['Atezolizumab', 'Placebo', 'Bevacizumab', 'Paclitaxel', 'Pemetrexed', 'Carboplatin']"
146,NCT04611776,"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer","['Atezolizumab', 'Placebo', 'Carboplatin', 'Cisplatin', 'Pemetrexed', 'Gemcitabine', 'Paclitaxel']"
147,NCT03726879,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","['Atezolizumab', 'Placebo', 'Doxorubicin', 'Cyclophosphamide', 'Paclitaxel', 'Trastuzumab', 'Pertuzumab', 'Trastuzumab Emtansine']"
148,NCT03371017,"A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer","['Atezolizumab', 'Placebo', 'Gemcitabine', 'Capecitabine', 'Carboplatin']"
149,NCT03603184,Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer,"['Atezolizumab', 'Placebos', 'Paclitaxel', 'Carboplatin']"
150,NCT02814669,"A Phase Ib, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination With Radium-223 Dichloride in Patients With Castrate-Resistant Prostate Cancer Who Have Progressed Following Treatment With an Androgen Pathway Inhibitor","['Atezolizumab', 'Radium-223 Dichloride']"
151,NCT03735121,"A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","['Atezolizumab', 'rHuPH20']"
152,NCT03422523,"A Phase II Study of Atezolizumab With Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Not Candidates for High-dose Therapy","['Atezolizumab', 'Rituximab', 'Gemcitabine 1000 mg', 'Oxaliplatin 100 MG']"
153,NCT03292172,"Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer","['Atezolizumab', 'RO6870810']"
154,NCT02650713,"An Open-Label, Multicenter, Dose Escalation and Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors","['Atezolizumab', 'RO6958688']"
155,NCT04267237,"A Phase II, Open-label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-doublet Chemotherapy in Patients Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-small Cell Lung Cancer","['Atezolizumab', 'RO7198457']"
156,NCT05645692,"A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of RO7247669 Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy","['Atezolizumab', 'RO7247669', 'Tiragolumab']"
157,NCT03101280,A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer,"['Atezolizumab', 'Rucaparib']"
158,NCT02304393,"An Open-Label, Multicenter, Dose-Escalation Phase IB Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of Selicrelumab (CD40 Agonist) in Combination With Atezolizumab (Anti PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumors","['Atezolizumab', 'Selicrelumab']"
159,NCT04832854,"A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","['Atezolizumab', 'Tiragolumab', 'Carboplatin', 'Cisplatin', 'Pemetrexed', 'Gemcitabine', 'Paclitaxel']"
160,NCT02794571,"A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors","['Atezolizumab', 'Tiragolumab', 'Carboplatin', 'Cisplatin', 'Pemetrexed', 'Paclitaxel', 'Etoposide', 'Capecitabine', 'Bevacizumab', 'Pembrolizumab']"
161,NCT05459129,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)","['Atezolizumab', 'Tiragolumab', 'Carboplatin', 'Paclitaxel']"
162,NCT04513925,"A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation","['Atezolizumab', 'Tiragolumab', 'Durvalumab']"
163,NCT04294810,"A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer","['Atezolizumab', 'Tiragolumab', 'Matching Placebo']"
164,NCT04933227,"A Phase II, Single-Arm Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)","['Atezolizumab', 'Tiragolumab', 'Oxaliplatin', 'Capecitabine']"
165,NCT04540211,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma","['Atezolizumab', 'Tiragolumab', 'Paclitaxel', 'Cisplatin', 'Atezolizumab Matching Placebo', 'Tiragolumab Matching Placebo']"
166,NCT04665843,"A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck","['Atezolizumab', 'Tiragolumab', 'Placebo']"
167,NCT03563716,"A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer","['Atezolizumab', 'Tiragolumab', 'Placebo']"
168,NCT04308785,"A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Study to Investigate the Efficacy and Safety of Atezolizumab With or Without Tiragolumab as Consolidation Therapy in Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed After Chemoradiotherapy","['Atezolizumab', 'Tiragolumab']"
169,NCT04873362,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","['Atezolizumab', 'Trastuzumab Emtansine', 'Placebo', 'Trastuzumab']"
170,NCT02924883,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy","['Atezolizumab', 'Trastuzumab emtansine']"
171,NCT04661150,"A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) and Trastuzumab in Combination With Capecitabine and Oxaliplatin (Xelox) in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction (GEJ)","['Atezolizumab', 'Trastuzumab', 'Capecitabine', 'Oxaliplatin']"
172,NCT03801304,Open Label Phase II Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer,"['Atezolizumab', 'Vinorelbine']"
173,NCT04660344,"A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy",['Atezolizumab']
174,NCT03024996,"A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy",['Atezolizumab']
175,NCT03548428,"Randomized Phase II, 2-arm Study of Immunomodulation With Atezolizumab Concomitant With High Dose Radiation (SBRT) Versus SBRT Alone in Patients With Oligometastatic Sarcomas",['Atezolizumab']
176,NCT03289962,"A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors","['Autogene cevumeran', 'Atezolizumab']"
177,NCT03799835,"An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer","['BCG', 'Atezolizumab']"
178,NCT03353831,Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial,"['Bevacizumab', 'Atezolizumab', 'Chemotherapy', 'Placebos']"
179,NCT03721653,Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients.,"['Bevacizumab', 'Irinotecan', 'Oxaliplatin', 'L-Leucovorin', '5-fluorouracil', 'Atezolizumab']"
180,NCT04158258,"A STUDY TO OBSERVE PATIENTS CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED BREAST CANCER IN LATIN AMERICA","['Bevacizumab', 'Trastuzumab', 'Ado-trastuzumab emtamsine', 'Pertuzumab', 'Atezolizumab', 'Capecitabine']"
181,NCT03154827,"A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study","['BL-8040', 'Atezolizumab']"
182,NCT04793399,"Multicenter, Open-label, Phase Ib/II Trial to Evaluate Safety and Efficacy for the Combination of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Myeloid Leukemia Patients","['Bosutinib 400 MG Monotherapy', 'Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection']"
183,NCT02500407,"An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia","['BTCT4465A (Mosunetuzumab) IV', 'Atezolizumab', 'BTCT4465A (Mosunetuzumab) SC']"
184,NCT05007613,A Single-arm Phase II Study of Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Who Failed a Platinum-based Chemotherapy,"['Cabozantinib 40 MG', 'Atezolizumab Injection']"
185,NCT03170960,A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,"['cabozantinib', 'atezolizumab', 'cabozantinib', 'cabozantinib']"
186,NCT04446117,"A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer","['Cabozantinib', 'Atezolizumab', 'Abiraterone Acetate', 'Enzalutamide', 'Prednisone']"
187,NCT04471428,"A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy","['Cabozantinib', 'Atezolizumab', 'Docetaxel']"
188,NCT03424005,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)","['Capecitabine', 'Atezolizumab', 'Ipatasertib', 'SGN-LIV1A', 'Bevacizumab', 'Chemotherapy (Gemcitabine + Carboplatin or Eribulin)', 'Selicrelumab', 'Tocilizumab', 'Nab-Paclitaxel', 'Sacituzumab Govitecan']"
189,NCT01898117,Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer,"['Carbo/cyclo', 'Carbo/cyclo + atezolizumab', 'Paclitaxel', 'Paclitaxel + Atezolizumab']"
190,NCT04042558,"A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","['Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab', 'Carboplatin + Pemetrexed + Atezolizumab']"
191,NCT03147040,AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial,"['Carboplatin', 'Atezolizumab']"
192,NCT03762018,A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma,"['Carboplatin', 'Pemetrexed', 'Bevacizumab', 'Atezolizumab']"
193,NCT02914470,"A Phase 1b to Assess the Safety and Tolerability of Carboplatin-cyclophosphamide Combined With Atezolizumab, an Antibody That Targets Programmed Death Ligand 1 (PD-L1), in Patients With Advanced Breast Cancer and Gynaecologic Cancer","['carbplatin, cyclophophamide, atezolizumab']"
194,NCT02291289,A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL),"['Cetuximab', 'FOLFOX induction regimen', 'Fluoropyrimidine (5-FU/LV or capecitabine)', 'Atezolizumab', 'Vemurafenib', 'Bevacizumab', 'Trastuzumab', 'Pertuzumab', 'Cobimetinib', '5-FU/LV']"
195,NCT03264066,"A Phase II, Open-Label, Multicenter, Multicohort Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors","['Cobimetinib', 'Atezolizumab', 'Atezolizumab Cohort 7']"
196,NCT03273153,"A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma","['Cobimetinib', 'Atezolizumab', 'Pembrolizumab']"
197,NCT03625141,A Phase II Two Cohort Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases,"['Cobimetinib', 'Atezolizumab', 'Vemurafenib']"
198,NCT03695380,"A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer","['Cobimetinib', 'Niraparib', 'Atezolizumab']"
199,NCT02322814,"A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer","['Cobimetinib', 'Paclitaxel', 'Placebo', 'Atezolizumab', 'Nab-Paclitaxel']"
200,NCT03312530,"A Phase Ib/II Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Patients With Relapsed and Refractory Multiple Myeloma","['Cobimetinib', 'Venetoclax', 'Atezolizumab']"
201,NCT00626197,"A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus","['Corticosteroids', 'Cyclophosphamide', 'Mycophenolate Mofetil', 'Ocrelizumab', 'Placebo', 'Azathioprine']"
202,NCT03818997,DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer: a Multi-center Phase II Trial,"['DKN-01', 'Atezolizumab', 'Paclitaxel']"
203,NCT01903993,"A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure","['Docetaxel', 'Atezolizumab']"
204,NCT00781612,"An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study","['Docetaxel', 'Paclitaxel', 'Pertuzumab', 'Trastuzumab', 'Trastuzumab Emtansine', 'Atezolizumab']"
205,NCT04984811,"A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC","['efineptakin alfa', 'Atezolizumab']"
206,NCT02708680,"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase","['entinostat', 'atezolizumab', 'Placebo']"
207,NCT04589845,Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial,"['Entrectinib', 'Entrectinib', 'Alectinib', 'Atezolizumab', 'Ipatasertib', 'Trastuzumab emtansine', 'Idasanutlin', 'Inavolisib', 'Belvarafenib', 'Pralsetinib']"
208,NCT04730999,"A Phase II, Single Arm Study of CarbopLatin Plus Etoposide With Bevacizumab and Atezolizumab in Patients With exTEnded-disease Small-cell Lung Cancer (SCLC)","['Etoposide', 'Carboplatin', 'Bevacizumab', 'Atezolizumab']"
209,NCT04597918,"An Exploratory, Prospective, Multi-Center, Open-Label, Single-Arm, Interventional, Phase IIB Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Patients With Diabetic Macular Edema Treated With Faricimab (RO6867461) - ALTIMETER STUDY",['Faricimab']
210,NCT05224102,"A Phase IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema",['Faricimab']
211,NCT05610319,"Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial",['Faricimab']
212,NCT05476926,"Real-World, Long-Term Data Collection to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY)",['Faricimab']
213,NCT04740931,"A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","['Faricimab', 'Aflibercept']"
214,NCT04740905,"A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion","['Faricimab', 'Aflibercept']"
215,NCT03823300,"A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)","['Faricimab', 'Aflibercept']"
216,NCT03823287,"A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA)","['Faricimab', 'Aflibercept']"
217,NCT02699450,"A Multiple-Center, Multiple-Dose, Randomized, Active Comparator-Controlled, Double-Masked, Parallel Group, 36-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema","['Faricimab', 'Ranibizumab']"
218,NCT02484690,"A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration","['Faricimab', 'Ranibizumab', 'Sham Procedure']"
219,NCT03038880,STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration,"['Faricimab', 'Ranibizumab', 'Sham Procedure']"
220,NCT04777201,"A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (AVONELLE-X)",['Faricimab']
221,NCT04432831,"A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema",['Faricimab']
222,NCT04544449,"A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Patients With Primary Progressive Multiple Sclerosis.","['fenebrutinib', 'ocrelizumab', 'placebo']"
223,NCT04592341,"A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Pharmacodynamic Effects of Once Weekly Administration of Gantenerumab in Participants With Early (Prodromal to Mild) Alzheimer's Disease",['Gantenerumab']
224,NCT04374253,"An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease","['Gantenerumab', 'Gantenerumab']"
225,NCT04339413,"An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease",['Gantenerumab']
226,NCT03236844,"A Multi-Center, Randomized, Open-Label, Single-Dose, Parallel Group Study to Investigate the Relative Bioavailability of Gantenerumab Produced With the G4 Process in Comparison to Gantenerumab Produced With the G3 Process Following Administration by Subcutaneous Injection in Healthy Volunteers",['Gantenerumab']
227,NCT02133937,"A Single-center, Randomized Open-label, Single-dose, Parallel Group Study to Investigate the Relative Bioavailability of a High Concentration Liquid Formulation (Hclf) in Prefilled Syringes Versus the Reference Lyophilized Formulation (Lyof) of Gantenerumab Following Administration by Subcutaneous Injection in Healthy Volunteers","['gantenerumab', 'gantenerumab']"
228,NCT01636531,"A Multi-center, Randomized Open-label, Single-dose, Parallel Group Investigation of the Relative Bioavailability, Tolerability and Dose-exposure Relationship of a High Concentration Liquid Formulation (HCLF) Versus a Lyophilized Formulation (LyoF) of RO4909832 (Gantenerumab) When Administered by su","['gantenerumab', 'gantenerumab']"
229,NCT00531804,"A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO4909832 Following Intravenous Infusion in AD Patients",['gantenerumab']
230,NCT05552157,"A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-part Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease","['Gantenerumab', 'Matching Placebo (Gantenerumab)']"
231,NCT05256134,"A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease","['Gantenerumab', 'Placebo']"
232,NCT03444870,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease","['Gantenerumab', 'Placebo']"
233,NCT03443973,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease","['Gantenerumab', 'Placebo']"
234,NCT02882009,"A Single-Center, Randomized, Open-Label, Parallel-Group, Placebo-Controlled, Cross-Over Study To Investigate the Impact of Speed of Injection and Site of Injection on Pain, Tolerability, Safety, and Pharmacokinetics Following Subcutaneous Administration of Gantenerumab in Healthy Volunteers","['Gantenerumab', 'Placebo']"
235,NCT02711423,"A Single-Center, Randomized, Investigator/Subject-Blind Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Gantenerumab Following SC Administration in Healthy Subjects","['Gantenerumab', 'Placebo']"
236,NCT01224106,"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment","['Gantenerumab', 'Placebo']"
237,NCT04623242,"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease","['Gantenerumab', 'Solanezumab', 'Matching Placebo (Gantenerumab)', 'Matching Placebo (Solanezumab)']"
238,NCT01760005,"A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease","['Gantenerumab', 'Solanezumab', 'Matching Placebo (Gantenerumab)', 'Matching Placebo (Solanezumab)', 'Gantenerumab', 'E2814', 'Lecanemab', 'Matching Placebo (E2814)']"
239,NCT05240131,"An Open Label Study Followed by a Randomised, Double-blind, Placebo-controlled, Parallel Group and an Extension Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).","['GB1211', 'Placebo', 'Atezolizumab']"
240,NCT05487235,"A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors","['GDC-1971', 'Atezolizumab', 'Omeprazole']"
241,NCT04449874,"A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","['GDC-6036', 'Atezolizumab', 'Cetuximab', 'Bevacizumab', 'Erlotinib', 'GDC-1971', 'Inavolisib']"
242,NCT04802759,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)","['Giredestrant', 'Abemaciclib', 'Ipatasertib', 'Inavolisib', 'Ribociclib', 'Everolimus', 'Samuraciclib', 'PH FDC SC', 'Palbociclib', 'Atezolizumab']"
243,NCT03533283,"An Open-Label, Multi-Center, Phase IB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","['Glofitamab', 'Atezolizumab', 'Obinutuzumab', 'Tocilizumab', 'Polatuzumab Vedotin', '89Zr-Df-IAB22M2C']"
244,NCT04313608,"A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma","['Glofitamab', 'Gemcitabine', 'Oxaliplatin', 'Mosunetuzumab', 'Obinutuzumab', 'Tocilizumab']"
245,NCT05468489,"A Randomized, Open-label Study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","['HLX10 + chemotherapy (carboplatin-etoposide)', 'Atezolizumab + chemotherapy (carboplatin-etoposide)']"
246,NCT04929223,"A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","['Inavolisib', 'Bevacizumab', 'Cetuximab', 'Atezolizumab', 'Tiragolumab', 'SY-5609', 'GDC-6036', 'FOLFOX']"
247,NCT01412333,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis","['Interferon beta-1a', 'Ocrelizumab-matching placebo', 'Ocrelizumab', 'Interferon beta-1a-matching placebo']"
248,NCT01247324,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis","['Interferon beta-1a', 'Ocrelizumab-matching placebo', 'Ocrelizumab', 'Interferon beta-1a-matching placebo']"
249,NCT04341259,A Phase I Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Patients With Locally Advanced Or Metastatic Solid Tumors.,['Ipatasertib']
250,NCT03341884,"A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Ipatasertib in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Subjects",['Ipatasertib']
251,NCT02536391,"A Phase 1, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of Ipatasertib (GDC-0068) in Healthy Subjects","['Ipatasertib (capsule)', 'Ipatasertib (tablet)']"
252,NCT02063581,"A Phase 1, Open-Label Study to Evaluate the Effect of Formulation on the Bioavailability of Ipatasertib (GDC-0068) in Healthy Subjects","['ipatasertib (Capsule)', 'ipatasertib (Tablet)']"
253,NCT04920708,Randomised Phase II Study of Induction Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression,"['Ipatasertib 300mg', 'Fulvestrant 500g', 'Palbociclib 75mg-125mg', 'CDK4/6 Inhibitor']"
254,NCT03072238,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer","['Ipatasertib', 'Abiraterone', 'Placebo', 'Prednisone/Prednisolone']"
255,NCT03673787,Ice-CAP: A Phase I Trial of Ipatasertib in Combination With Atezolizumab in Patients With Advanced Solid Tumours With PI3K Pathway Hyperactivation,"['ipatasertib', 'Atezolizumab']"
256,NCT04404140,"A Phase Ib, Open-Label, Multicenter Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer.","['Ipatasertib', 'Atezolizumab', 'Docetaxel']"
257,NCT04464174,"A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in Combination With Non-Taxane Chemotherapy Agents for Taxane-Pretreated Unresectable Locally Advanced or Metastatic TNBC Patients","['Ipatasertib', 'Capecitabine', 'Eribulin', 'Carboplatin', 'Gemcitabine']"
258,NCT04931342,"A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","['Ipatasertib', 'Cobimetinib', 'Trastuzumab Emtansine', 'Atezolizumab', 'Bevacizumab', 'Paclitaxel', 'Giredestrant', 'Abemaciclib', 'Inavolisib', 'Palbociclib', 'Letrozole', 'Olaparib', 'Luteinizing Hormone-Releasing Hormone (LHRH) Agonists']"
259,NCT04650581,A Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor,"['Ipatasertib', 'Fulvestrant']"
260,NCT03222310,Effect of a Potent CYP3A and P-gp Inhibitor (Itraconazole) on Ipatasertib Pharmacokinetics in Healthy Subjects,"['Ipatasertib', 'Itraconazole']"
261,NCT03800836,"A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer","['Ipatasertib', 'Paclitaxel', 'Atezolizumab', 'Nab-Paclitaxel', 'AC']"
262,NCT03337724,"A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer","['Ipatasertib', 'Paclitaxel', 'Placebo']"
263,NCT02162719,"A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer","['Ipatasertib', 'Paclitaxel', 'Placebo']"
264,NCT04060862,A Phase Ib/III Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer,"['Ipatasertib', 'Placebo', 'Palbociclib', 'Fulvestrant']"
265,NCT04253561,"A Phase Ib Study of Ipatasertib, an AKT Inhibitor, in Combination With Pertuzumab Plus Trastuzumab in Patients With PI3KCA-mutant, HER2-positive Locally Advanced or Metastatic Breast Cancer","['Ipatasertib', 'Trastuzumab', 'Pertuzumab']"
266,NCT03961698,"A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination With Front-line Treatment Regimens in Patients With Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma","['IPI-549 (eganelisib)', 'Atezolizumab', 'nab-paclitaxel', 'Bevacizumab']"
267,NCT01872689,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis","['Lebrikizumab', 'Pirfenidone', 'Placebo']"
268,NCT00476996,"A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-α Therapy","['Leflunomide', 'Methotrexate', 'Ocrelizumab', 'Ocrelizumab', 'Placebo']"
269,NCT02707640,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N-Acetylcysteine in Patients With Idiopathic Pulmonary Fibrosis With Background Treatment of Pirfenidone","['Matching Placebo', 'N-acetylcysteine', 'Pirfenidone']"
270,NCT00673920,"A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy","['Methotrexate', 'Ocrelizumab', 'Placebo']"
271,NCT00485589,"A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab in Combination With Methotrexate (MTX) Compared to MTX Alone in Methotrexate- Naive Patients With Active Rheumatoid Arthritis","['Methotrexate', 'Ocrelizumab', 'Placebo']"
272,NCT00406419,"A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment","['Methotrexate', 'ocrelizumab', 'Placebo']"
273,NCT05207670,"An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies","['Mosunetuzumab (Cohorts A-C)', 'Mosunetuzumab (Cohorts D-E)', 'Tocilizumab']"
274,NCT03671018,"An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma","['Mosunetuzumab (IV)', 'Mosunetuzumab (SC)', 'Polatuzumab vedotin', 'Tocilizumab', 'Rituximab']"
275,NCT04246086,"A Phase Ib/II, Open-Label, Multicenter Study With a Non-Randomized Stage Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab Plus Lenalidomide (+Len), and a Randomized Stage Evaluating the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Patients With Follicular Lymphoma","['Mosunetuzumab (IV)', 'Tocilizumab', 'Lenalidomide', 'Mosunetuzumab (SC)']"
276,NCT03677154,A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma,"['Mosunetuzumab Intravenous (IV)', 'Mosunetuzumab Subcutaneous (SC)', 'Polatuzumab Vedotin', 'Tocilizumab']"
277,NCT05315713,"A Phase Ib/II Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","['Mosunetuzumab SC', 'Tiragolumab', 'Atezolizumab']"
278,NCT04712097,"Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy","['Mosunetuzumab', 'Lenalidomide', 'Rituximab', 'Tociluzumab']"
279,NCT03677141,"A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma","['Mosunetuzumab', 'Polatuzumab Vedotin', 'Rituxumab', 'Cyclophosphamide', 'Doxorubicin', 'Vincristine', 'Prednisone', 'Tocilizumab']"
280,NCT05171647,"A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","['Mosunetuzumab', 'Polatuzumab vedotin', 'Tocilizumab', 'Rituximab', 'Gemcitabine', 'Oxaliplatin']"
281,NCT05155345,"A Phase Ib, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus","['Mosunetuzumab', 'Tocilizumab']"
282,NCT05091424,"A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","['Mosunetuzumab', 'Tocilizumab']"
283,NCT03029832,"A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy","['MOXR0916', 'Atezolizumab']"
284,NCT03193190,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","['Nab-Paclitaxel', 'Gemcitabine', 'Oxaliplatin', 'Leucovorin', 'Fluorouracil', 'Atezolizumab', 'Cobimetinib', 'PEGPH20', 'BL-8040', 'Selicrelumab', 'Bevacizumab', 'RO6874281', 'AB928', 'Tiragolumab', 'Tocilizumab', 'LSTA1']"
285,NCT02598193,"An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet®) in Combination With Nintedanib (Ofev®) in Patients With Idiopathic Pulmonary Fibrosis","['Nintedanib', 'Pirfenidone']"
286,NCT05116202,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)","['Nivolumab', 'Ipilimumab', 'RO7247669', 'Atezolizumab', 'Tiragolumab']"
287,NCT04962126,Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy,"['Obinutuzumab 25 MG/1 ML Intravenous Solution', 'Atezolizumab 1200 MG/40mL Intravenous Solution']"
288,NCT03866239,"A Phase Ib, Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Patients With Previously Treated Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High CEACAM5 Expression","['Obinutuzumab', 'Atezolizumab', 'Cibisatamab', 'Tocilizumab']"
289,NCT03599245,"A Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trials",['Ocrelizumab']
290,NCT05269004,"A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study To Evaluate The Long-Term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis",['Ocrelizumab']
291,NCT05208840,Open-Label Multicenter Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis,['Ocrelizumab']
292,NCT04998851,"A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab",['Ocrelizumab']
293,NCT04998812,"A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy",['Ocrelizumab']
294,NCT04075266,"An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis",['Ocrelizumab']
295,NCT03593590,A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY,['Ocrelizumab']
296,NCT03523858,"An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis",['Ocrelizumab']
297,NCT03085810,"An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis",['Ocrelizumab']
298,NCT02723071,"An Open-label, Multicentre, Dose-escalating Phase I/II Trial of 3-weekly Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)",['Ocrelizumab']
299,NCT04377555,"An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab",['Ocrelizumab']
300,NCT02807285,"An Open Label, MultiCenter, Expanded-Access Program for Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis",['Ocrelizumab']
301,NCT02637856,An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment,"['Ocrelizumab', 'Ocrelizumab']"
302,NCT03691077,A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714,['Ocrelizumab']
303,NCT03589105,"An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis","['Ocrelizumab 300 mg', 'Ocrelizumab 600 mg']"
304,NCT03606460,"A Phase IIIb, Open-Label Study To Evaluate The Safety And Tolerability Of Shorter Infusions Of Ocrelizumab In Patients With Primary Progressive And Relapsing Multiple Sclerosis","['Ocrelizumab Dose 1', 'Ocrelizumab Dose 2 and Dose 3']"
305,NCT05232825,"A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","['Ocrelizumab IV', 'Ocrelizumab SC', 'Methylprednisolone IV', 'Diphenhydramine IV', 'Dexamethasone given orally', 'Desloratadine given orally']"
306,NCT04548999,"A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis","['Ocrelizumab', 'Ocrelizumab', 'Antihistamine', 'Methylprednisolone']"
307,NCT04544436,"A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis","['Ocrelizumab', 'Ocrelizumab', 'Antihistamine', 'Methylprednisolone']"
308,NCT04035005,"A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis","['Ocrelizumab', 'Placebo']"
309,NCT02720120,"A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response","['Ocrelizumab', 'Placebo']"
310,NCT03972306,"A Phase Ib, Open-Label, Multicenter Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis","['Ocrelizumab', 'Ocrelizumab', 'rHuPH20']"
311,NCT05123703,"A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis","['Ocrelizumab', 'Fingolimod']"
312,NCT01194570,"A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis",['Ocrelizumab']
313,NCT02688985,"An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis","['Ocrelizumab', 'Methyloprednisolone', 'Antihistamine']"
314,NCT03038100,"A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","['Paclitaxel', 'Carboplatin', 'Atezolizumab', 'Bevacizumab', 'Atezolizumab Placebo']"
315,NCT02925234,"A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile","['Panitumumab', 'Olaparib', 'Dabrafenib', 'Nilotinib', 'Trametinib', 'Erlotinib', 'Trastuzumab and Pertuzumab (combination treatment)', 'Vemurafenib and Cobimetinib (combination treatment)', 'Vismodegib', 'Regorafenib', 'Nivolumab', 'Afatinib', 'Dabrafenib and trametinib', 'Ribociclib', 'Lenvatinib', 'Pembrolizumab', 'Durvalumab', 'Rucaparib', 'Axitinib', 'Palbociclib', 'Crizotinib', 'Sunitinib', 'Cabozantinib', 'Abemaciclib', 'Alectinib', 'Atezolizumab and Bevacizumab', 'Ipilimumab and nivolumab', 'Entrectinib', 'Talazoparib', 'Dacomitinib', 'Lorlatinib', 'Erdafitinib', 'Alpelisib']"
316,NCT03840200,"A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer","['Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib', 'Part 1, Dose level 2b and dose level 3: Ipatasertib', 'Part 1, Dose Level 1 and Dose Level 2b: Rucaparib', 'Part 1, Dose Level 2a and Dose Level 3: Rucaparib']"
317,NCT03208933,Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice,['Pirfenidone']
318,NCT03115619,"A Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Quality of Life in Patients in Greece With Idiopathic Pulmonary Fibrosis Under Treatment With Pirfenidone - The Pneumon Study",['Pirfenidone']
319,NCT02699879,Post-Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting,['Pirfenidone']
320,NCT02622477,Clinical Course of Treatment With ESBRIET in Patients With Mild to Moderate IPF,['Pirfenidone']
321,NCT02525484,"A Phase I, Open-Label, Randomized, Four-Treatment Period, Four-Sequence, Single-Dose, Crossover, Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers",['Pirfenidone']
322,NCT00080223,"An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis",['Pirfenidone']
323,NCT03385668,"A Pilot Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Pulmonary Fibrosis With Anti-myeloperoxydase (MPO) Antibodies or With Anti-MPO Associated Vasculitis.""",['Pirfenidone']
324,NCT00662038,An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF),['pirfenidone']
325,NCT03099187,"Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD","['Pirfenidone', 'Placebo']"
326,NCT02932566,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE)","['Pirfenidone', 'Placebo']"
327,NCT02951429,"A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Group 3 Pulmonary Hypertension","['Pirfenidone', 'Placebo', 'Sildenafil']"
328,NCT02648048,"A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","['Pirfenidone', 'Vismodegib']"
329,NCT04653831,Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial,['Pirfenidone']
330,NCT03281954,"A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo","['Placebo', 'Atezolizumab']"
331,NCT03598270,"A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months","['Placebo', 'Carboplatin', 'Paclitaxel', 'Niraparib', 'Gemcitabine', 'Pegylated liposomal doxorubicin (PLD)', 'Atezolizumab']"
332,NCT02051608,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients","['Placebo', 'Gantenerumab']"
333,NCT00676715,"Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS","['Placebo', 'Ocrelizumab', 'Avonex']"
334,NCT05243862,Phase II Study of PolyPEPI1018 Vaccine in Combination With Atezolizumab in Participants With Relapsed or Refractory Microsatellite-stable Metastatic Colorectal Cancer.,"['PolyPEPI1018', 'Atezolizumab']"
335,NCT00539838,"A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus","['Prednisone', 'Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)', 'Methylprednisolone', 'Ocrelizumab', 'Placebo']"
336,NCT03555149,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)","['Regorafenib', 'Atezolizumab', 'Imprime PGG', 'Bevacizumab', 'Isatuximab', 'Selicrelumab', 'Idasanutlin', 'AB928']"
337,NCT04303858,"An Open-Label, Multicenter, Randomized, Dose-Escalation and Extension, Phase IA/IB Study to Evaluate Safety and Anti-Tumor Activity of RO7284755, A PD-1 Targeted IL-2 Variant (IL-2V) Immunocytokine, Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors","['RO7284755', 'Atezolizumab']"
338,NCT04642365,"An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors","['RO7296682', 'Atezolizumab']"
339,NCT04857138,"An Open-Label, Multicenter, Dose-Escalation and Expansion, Phase I Study to Evaluate Safety, Pharmacokinetics, And Anti-Tumor Activity of RO7300490, A Fibroblast Activation Protein-α (FAP) Targeted CD40 Agonist, as Single Agent or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors","['RO7300490', 'Atezolizumab']"
340,NCT05581004,"A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors","['RO7502175', 'Atezolizumab']"
341,NCT03654833,Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma,"['Rucaparib', 'Abemaciclib', 'pembrolizumab & bemcentinib', 'Atezolizumab & Bevacizumab', 'Dostarlimab and Niraparib']"
342,NCT05169515,"A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma","['SC Mosunetuzumab', 'IV Glofitamab', 'CC-220', 'CC-99282', 'Obinutuzumab', 'Tocilizumab']"
343,NCT03892525,Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma,"['Selicrelumab', 'Atezolizumab']"
344,NCT03386721,"An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa (RO6874281), an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors","['simlukafusp alfa', 'Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody', 'Gemcitabine', 'Vinorelbine']"
345,NCT05661578,"A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors",['Tiragolumab and Atezolizumab IV FDC']
346,NCT04300647,"A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer","['Tiragolumab', 'Atezolizumab']"
347,NCT04256421,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","['Tiragolumab', 'Atezolizumab', 'Carboplatin', 'Etoposide', 'Placebo']"
348,NCT04665856,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","['Tiragolumab', 'Atezolizumab', 'Carboplatin', 'Etoposide', 'Tiragolumab Matching Placebo']"
349,NCT04584112,"A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer","['Tiragolumab', 'Atezolizumab', 'Nab-paclitaxel', 'Tiragolumab', 'Atezolizumab', 'Nab-paclitaxel', 'Carboplatin', 'Doxorubicin', 'Cyclophosphamide', 'Granulocyte colony-stimulating factor (G-CSF)', 'Granulocyte-macrophage colony-stimulating factor (GM-CSF)']"
350,NCT04619797,"A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer","['Tiragolumab', 'Atezolizumab', 'Pemetrexed', 'Carboplatin', 'Cisplatin', 'Tiragolumab Matching Placebo', 'Pembrolizumab']"
351,NCT04543617,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","['Tiragolumab', 'Atezolizumab', 'Tiragolumab Matching Placebo', 'Atezolizumab Matching Placebo']"
352,NCT04045028,"A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","['Tiragolumab', 'Daratumumab/rHuPH20', 'Rituximab', 'Atezolizumab']"
353,NCT04740918,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo in Patients With HER2-Positive and PD-L1-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab- (+/- Pertuzumab) and Taxane-Based Therapy (KATE3)","['Trastuzumab Emtansine', 'Atezolizumab']"
354,NCT03595592,"Atezolizumab, Pertuzumab and Trastuzumab With Chemotherapy as Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)","['Trastuzumab', 'Pertuzumab', 'Carboplatin', 'Paclitaxel', 'Doxorubicin', 'Cyclophosphamide', 'Atezolizumab']"
355,NCT02091141,"My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents","['Trastuzumab', 'Pertuzumab', 'Erlotinib', 'Vemurafenib', 'Cobimetinib', 'Vismodegib', 'Alectinib', 'Atezolizumab']"
356,NCT03041311,"Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)","['Trilaciclib', 'Placebo', 'Carboplatin', 'Etoposide', 'Atezolizumab']"
357,NCT04422210,"A Phase Ib Dose-Escalation and Dose-Expansion Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Patients With Untreated Extensive-Stage Small Cell Lung Cancer.","['Venetoclax', 'Atezolizumab', 'Carboplatin', 'Etoposide']"
358,NCT04250155,"A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors","['XmAb24306', 'Atezolizumab', 'XmAb24306']"
359,NCT05396937,"Efficacy and Safety of Multifocal Stereotactic Radiotherapy Combined With Atezolizumab and Bevacizumab in the Treatment of Metastatic Hepatocellular Carcinoma: An Open-label, Single-arm Exploratory Study","['Atezolizumab Injection [Tecentriq]', 'Bevacizumab']"
